Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Current Assets (2016 - 2025)

Historic Current Assets for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $347.3 million.

  • Vanda Pharmaceuticals' Current Assets fell 2087.72% to $347.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $347.3 million, marking a year-over-year decrease of 2087.72%. This contributed to the annual value of $347.3 million for FY2025, which is 2087.72% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Current Assets stood at $347.3 million for Q4 2025, which was down 2087.72% from $367.5 million recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Current Assets peaked at $536.6 million during Q3 2023, and registered a low of $347.3 million during Q4 2025.
  • In the last 5 years, Vanda Pharmaceuticals' Current Assets had a median value of $443.0 million in 2021 and averaged $456.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 1855.4% in 2021, then plummeted by 2087.72% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Current Assets (Quarter) stood at $478.3 million in 2021, then rose by 8.57% to $519.3 million in 2022, then decreased by 16.63% to $432.9 million in 2023, then increased by 1.37% to $438.9 million in 2024, then decreased by 20.88% to $347.3 million in 2025.
  • Its Current Assets stands at $347.3 million for Q4 2025, versus $367.5 million for Q3 2025 and $394.9 million for Q2 2025.